Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
- Merck Receives First U.S. Patent for Improved CRISPR Genome-Editing Method on February 19, 2019 at 5:25 am
"This is great news for researchers in the U.S., as they now have more gene-editing options that accelerate drug development." Merck's proxy-CRISPR is a new genome-editing technique ... 16:30 GMT Merc... […]
- WHO forms human genome editing panel in wake of controversy on February 18, 2019 at 9:17 am
The WHO's decision is thought to be motivated largely by a recent controversy in China, where Chinese researcher Dr He Jiankui stunned the global scientific community with his announcement that he had ... […]
- NIH Director explores the ethics of gene editing technology on February 14, 2019 at 9:06 am
Collins went on to discuss ways in which the discovery of CRISPR-Cas9 has not only generated discussions on the ethics of editing a person’s genome but has also already led to the application of the t... […]
- Exosome-mediated horizontal gene transfer occurs in double-strand break repair during genome editing on February 8, 2019 at 2:32 am
The CRISPR-Cas9 system has been successfully applied in many organisms as a powerful genome-editing tool. Undoubtedly ... this study highlight an emerging new risk for this leading-edge technology. Th... […]
- Scientists crack the CRISPR code for precise human genome editing on December 13, 2018 at 8:04 am
Illustration of the CRISPR/Cas9 genome editing system. Credit ... Despite the wide use of the CRISPR system, rational application of the technology has been hindered by the assumption that the outcome ... […]
- CRISPR Cas9 Genome Editing Market Worth $5.3 Billion by 2025 on November 19, 2018 at 6:39 am
This report focuses on the CRISPR-Cas9 genome editing tools including its technology, market, and patent landscape. The report forecasts the sizes and trends of the global market as well as its sub-se... […]
- Intellia Therapeutics (NTLA) Educational Briefing On Interference Proceedings Relating To CRISPR/Cas9 Genome Editing Technology Patents - Slideshow on August 29, 2018 at 10:05 am
The following slide deck was published by Intellia Therapeutics in conjunction with this event. 124 Click to enlarge Notes: The following slide deck was published by Intellia Therapeutics in conjuncti... […]
- Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer on August 7, 2018 at 5:00 pm
August 08, 2018 08:30 ET | Source: Yield10 Bioscience, Inc. WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create ste... […]
- Genome damage from CRISPR/Cas9 gene editing higher than thought on July 16, 2018 at 8:00 am
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells ... It is important that anyone thinking of using this technology for gene therapy proceeds with caution, a... […]
- CRISPR pioneer Jennifer Doudna explains gene-editing technology in Prather Lectures on May 16, 2018 at 2:06 pm
Jennifer Doudna, the gene-editing pioneer whose breakthrough in CRISPR technology has ... killing them. The CRISPR/Cas9 array allows the bacteria to recognize future attacks and, because it becomes pa... […]
via Google News and Bing News